All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: A PRECIS database study

Diabetes, Obesity and Metabolism

Volumn 11, Issue 2, 2009, Pages 102-108

  Doshi, K B ^a   Kashyap, S R ^a,b   Brennan, D M ^a   Hoar, B M ^a   Cho, L ^a   Hoogwerf, B J ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Diabetes; Lipids; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENTIATION;

EID: 58149348524     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00908.x     Document Type: Article

References (25)

1. Reaven GM. Role of insulin resistance and human disease. Diabetes Banting Lecture 1988; 37: 1595-1607.
2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 3173-3194.
3. Kashyap SR, DeFronzo RA. The insulin resistance syndrome: Physiological considerations. Diab Vasc Dis Res 2007; 4: 13-19.
4. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
5. Kahn R. The metabolic syndrome (emperor) wears no clothes. Diabetes Care 2006; 29: 1693-1696.
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
7. Keiman M, Winkleby MA. Identifying patients for weight loss treatment: an empirical evaluation of the NHLBI obesity education initiative expert panel treatment recommendations. Arch intern med 2000; 160: 2169-2276.
8. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982; 247: 2543-2546.
9. Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res 2004; 10: 822-824.
10. Haffner SM, Lehto S, Rönnemaa T, PyöräläK, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
11. Whiteley L, Hole D, Padmanabhan S, Isles C. Should diabetes be considered a coronary heart disease risk equivalent. Diabetes Care 2005; 28: 1588-1593.
12. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as a predictor of type 2 diabetes. The San Antonio heart study. Diabetes Care 2003; 26: 3153-3159.
13. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
14. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes Care 2001; 24: 683-689.
15. Hu FB, Stampfer MJ, Solomon CG, et al. The Impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch Intern Med 2001; 161: 1717-1723.
16. Alexander CM, Landsman PB, Teusch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary artery disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
17. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
18. Yilmaz MB, Guray Y, Guray U, Biyikoglu SF, Tandogan I, Korkmaz S. Metabolic syndrome increases the risk of significant coronary artery involvement in patients with peripheral artery disease. Coron Artery Dis 2006; 17: 529-532.
19. Brevetti G, Schiano V, Sirico G, Giugliano G, Laurenzano E, Chiariello M. Metabolic syndrome in peripheral arterial disease: Relationship with severe peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 2006; 44: 101-107.
20. Hoogwerf BJ, Sprecher DL, Pearce GL, et al. Blood glucose concentrations ≤ 125 mg/dl and coronary heart disease risk. Am J Cardiol 2002; 89: 596-599.
21. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22: 696-699.
22. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
23. DECODE study group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
24. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30: 1292-1293.
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.